ImpediMed Secures $15m Growth Capital Funding
Summary
New round will help fuel commercialization efforts in support of ImpediMeds platform technology for the detection and monitoring of lymphedema.CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Armentum Partners acted as the Companys exclusive financial advisor on this transaction.With this new funding in place, ImpediMeds capital base is well equipped to support the continued execution of its commercial strategy. ImpediMeds platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with U.S. health payors now providing coverage for over 258 million covered lives.Lymphedema, a common consequence of cancer treatment, is challenging to detect before symptoms appear. ""We believe that the SOZO Digital Health Platform is revolutionizing how clinicians assess and manage fluid and body composition, ultimately improving patient outcomes," said JD Tamas, Director of Underwriting at SWK Holdings. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMeds SaaS subscription-based business.1 Used with permission of the American College of Surgeons, Chicago, Illinois.